Literature DB >> 10798558

Evaluation of a PCR-immunoassay technique for detection of Neisseria meningitidis in cerebrospinal fluid and peripheral blood.

R J Seward1, K J Towner1.   

Abstract

A multiplex PCR-immunoassay for the rapid diagnosis of bacterial meningitis from cerebrospinal fluid (CSF) or peripheral blood was compared with conventional microbiological techniques used in the routine diagnostic laboratory. The multiplex PCR was designed to detect simultaneously a universal conserved sequence coding for bacterial 16S rRNA and the Neisseria meningitidis porA gene. The PCR-immunoassay had a detection limit of (3-5) x 10(2) cfu/ml (equivalent to 1-3 cfu/PCR) with spiked CSF or blood samples, compared with (3-5) x 10(3) cfu/ml for PCR followed by conventional agarose gel electrophoresis for detection of PCR products. Of 294 CSF samples from patients suspected on clinical grounds of suffering from meningitis, the PCR-immunoassay detected bacterial DNA in 29 CSF samples, 15 of which were also positive for N. meningitidis DNA. The 29 positive CSF samples comprised 25 samples that were also reported positive and four that were reported negative by conventional methodology; the latter four were all positive for N. meningitidis by the PCR-immunoassay. Of 173 peripheral blood samples examined, the PCR-immunoassay detected bacterial DNA in 18 samples, 14 of which were also positive for N. meningitidis DNA. In comparison, only 10 samples were reported positive for N. meningitidis by conventional methodology. All negative PCR-immunoassay results correlated with those obtained by conventional methodology for both CSF and blood samples. The sensitivity and speed of the PCR-immunoassay system indicated that it could be used as a routine diagnostic test for meningococcal meningitis, enabling a diagnosis to be made within 4 h of receipt of the specimen.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10798558     DOI: 10.1099/0022-1317-49-5-451

Source DB:  PubMed          Journal:  J Med Microbiol        ISSN: 0022-2615            Impact factor:   2.472


  7 in total

Review 1.  PCR in diagnosis of infection: detection of bacteria in cerebrospinal fluids.

Authors:  Yoshimasa Yamamoto
Journal:  Clin Diagn Lab Immunol       Date:  2002-05

2.  Use of pre- and post-test probability of disease to interpret meningococcal PCR results.

Authors:  H C Van Woerden; A Howard; M Lyons; D Westmoreland; M Thomas
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2004-07-28       Impact factor: 3.267

Review 3.  Prospects for vaccine prevention of meningococcal infection.

Authors:  Lee H Harrison
Journal:  Clin Microbiol Rev       Date:  2006-01       Impact factor: 26.132

4.  Use of robotized DNA isolation and real-time PCR to quantify and identify close correlation between levels of Neisseria meningitidis DNA and lipopolysaccharides in plasma and cerebrospinal fluid from patients with systemic meningococcal disease.

Authors:  Reidun Øvstebø; Petter Brandtzaeg; Berit Brusletto; Kari Bente Foss Haug; Knut Lande; Ernst Arne Høiby; Peter Kierulf
Journal:  J Clin Microbiol       Date:  2004-07       Impact factor: 5.948

5.  Prospective study of a real-time PCR that is highly sensitive, specific, and clinically useful for diagnosis of meningococcal disease in children.

Authors:  Penelope A Bryant; Hua Yi Li; Angelo Zaia; Julia Griffith; Geoff Hogg; Nigel Curtis; Jonathan R Carapetis
Journal:  J Clin Microbiol       Date:  2004-07       Impact factor: 5.948

Review 6.  Bench-to-bedside review: the promise of rapid infection diagnosis during sepsis using polymerase chain reaction-based pathogen detection.

Authors:  Paul M Dark; Paul Dean; Geoffrey Warhurst
Journal:  Crit Care       Date:  2009-07-15       Impact factor: 9.097

Review 7.  Meningococcal serogroups A, C, W-135, and Y tetanus toxoid conjugate vaccine: a new conjugate vaccine against invasive meningococcal disease.

Authors:  Carine P Hedari; Rima W Khinkarly; Ghassan S Dbaibo
Journal:  Infect Drug Resist       Date:  2014-04-03       Impact factor: 4.003

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.